HUTCHMED (China) (HCM) Change in Accured Expenses (2015 - 2025)
HUTCHMED (China)'s (HCM) quarterly Change in Accured Expenses came in at $221.1 million in Q2 2025, down 11.3% year-on-year from $249.2 million in Q2 2024, and down 99.33% on a QoQ basis from $32.9 billion in Q4 2024.
HUTCHMED (China) (HCM) Change in Accured Expenses (2015 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 11 years of Change in Accured Expenses data on file, last reported at $221.1 million in Q2 2025.
- On a quarterly basis, Change in Accured Expenses fell 11.3% year-over-year to $221.1 million in Q2 2025; TTM through Jun 2025 was $221.1 million, a 11.3% decrease from a year earlier, with the FY2025 full-year figure at -$48.6 million, down 2095.52% from the prior year.
- Change in Accured Expenses for Q2 2025 stood at $221.1 million, down from $32.9 billion in the prior quarter.
- Over the last five years, Change in Accured Expenses for HCM reached as high as $34.7 billion in Q4 2023 and fell as low as $27.1 million in Q4 2021.
- Historically, Change in Accured Expenses has averaged $6.9 billion across 5 years, with a median of $224.1 million in 2023.
- Across the five-year window, Change in Accured Expenses soared 102575.61% in 2023 and slipped 11.3% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $27.1 million in 2021, then advanced by 24.98% to $33.8 million in 2022, then surged by 102575.61% to $34.7 billion in 2023, then fell by 5.15% to $32.9 billion in 2024, then tumbled by 99.33% to $221.1 million in 2025.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $221.1 million in Q2 2025, $32.9 billion in Q4 2024, and $249.2 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | HUTCHMED (China) | 9.55 Bn | 9.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 221.06 Mn |
| Jun 30, 2025 | 221.06 Mn |
| Dec 31, 2024 | 32.95 Bn |
| Dec 31, 2024 | 32.95 Bn |
| Jun 30, 2024 | 249.22 Mn |
| Jun 30, 2024 | 249.22 Mn |
| Dec 31, 2023 | 34.73 Bn |
| Dec 31, 2023 | 34.73 Bn |
| Jun 30, 2023 | 227.21 Mn |
| Jun 30, 2023 | 227.21 Mn |
| Dec 31, 2022 | 33.83 Mn |
| Dec 31, 2022 | 33.83 Mn |
| Jun 30, 2022 | 233.61 Mn |
| Jun 30, 2022 | 233.61 Mn |
| Dec 31, 2021 | 27.07 Mn |
| Dec 31, 2021 | 27.07 Mn |
| Jun 30, 2021 | 181.61 Mn |
| Jun 30, 2021 | 181.61 Mn |
| Mar 31, 2021 | 150.33 Mn |
| Mar 31, 2021 | 150.33 Mn |